ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 40.865

Change

-0.25 (-0.60)%

Market Cap

USD 0.40B

Volume

400.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.07 (+0.25%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.15 (+0.29%)

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.16 (+0.28%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.07 (+0.43%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

+1.45 (+0.60%)

USD 52.42B
VUSA:F Vanguard Funds Public Limited ..

-0.77 (-0.70%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

N/A

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.02 (-0.23%)

USD 38.52B
0ZC:F Zscaler Inc

+3.40 (+1.90%)

USD 37.92B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.08% 59% D- 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.08% 59% D- 46% F
Trailing 12 Months  
Capital Gain 7.06% 45% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.06% 41% F 46% F
Trailing 5 Years  
Capital Gain 56.00% 80% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.00% 79% B- 57% F
Average Annual (5 Year Horizon)  
Capital Gain 12.63% 78% C+ 70% C-
Dividend Return 12.63% 76% C+ 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.84% 63% D 89% A-
Risk Adjusted Return 116.54% 98% N/A 98% N/A
Market Capitalization 0.40B 58% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike